116856-18-9

Usage

Uses

Used in Pharmaceutical Research:
5-Formamide-1-(2-formyloxyethyl)pyrazole is utilized as a building block in the synthesis of complex organic molecules, particularly for the development of new drugs. Its potential bioactivity and reactivity contribute to the creation of innovative pharmaceutical compounds.
Used in Organic Synthesis:
In the field of organic synthesis, 5-Formamide-1-(2-formyloxyethyl)pyrazole serves as a key intermediate, facilitating the construction of various organic molecules. Its ability to engage in multiple chemical reactions makes it an indispensable component in the synthesis of a broad range of organic compounds.
Used in Drug Development:
5-Formamide-1-(2-formyloxyethyl)pyrazole is employed as a precursor in drug development, where its unique structure and reactivity are leveraged to create novel therapeutic agents. Its potential applications in this area highlight its importance in advancing pharmaceutical innovation.

InChI:InChI=1/C7H9N3O3/c11-5-8-7-1-2-9-10(7)3-4-13-6-12/h1-2,5-6H,3-4H2,(H,8,11)

Upstream product

• 64-18-6 formic acid 
• 73616-27-0 5-amino-1-(2-hydroxyethyl)-1H-pyrazole 

Relevant academic research and scientific papers

Studies on 3'-quaternary ammonium cephalosporins-IV. Synthesis and antibacterial activity of 3'-(2-alkyl-3-aminopyrazolium)cephalosporins related to FK037

The synthesis and in vitro antibacterial activity of 7β-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido] cephalosporins bearing various 2-alkyl-3-aminopyrazolium groups at the 3-position are described. Antibacterial activity against MRSA was affected by the nature of the substituent at the 2-position on the 3'-aminopyrazolium groups. Among the cephalosporins prepared in this study, 7β-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[3-amino-2-(2 -hydroxyethyl)-pyrazolio]methyl-3-cephem-4-carboxylate sulfate (23e, FK037) showed extremely potent broad-spectrum activity against both Gram-positive bacteria including MRSA, and Gram-negative bacteria including Pseudomonas aeruginosa. In particular, the in vivo activity against MRSA of FK037 was the highest of all the β-lactam antibiotics tested.

Cephem compound

The invention relates to antimicrobial compounds of the formula: STR1 wherein R1 is amino or a protected amino, R2 is ethyl, propyl or lower alkenyl, R3 is COO θ, carboxy or a protected carboxy, R4 is hydroxy(lower)alkyl or protected hydroxy(lower)alkyl, R5 is amino or a protected amino, Xθ is an anion, and n is 0 or 1, or, R1, R3, R5, Xθ and n are each as defined above, R2 is lower alkyl, and R4 is 3-hydroxypropyl, with proviso that (i) when R3 is COOθ, then n is 0, and (ii) when R3 is carboxy or a protected carboxy, then n is 1, or a pharmaceutically acceptable salt thereof.

Cephem compounds and processes for preparation thereof

7 β-[2-5 amino-1, 2, 4 thiadiazol-3yl) 2(carboxy lower alkyleneoxyimino) acetamido]-3-(3-amino-2-alkyl-1-pyrazolio) methyl 3 cephem 4 carboxylates are prepared. They are antibiotics.

Cephem compound and a process for preparation thereof

The object of the invention is a new cephem compound with antimicrobial activity used for the treatment of infectious diseases of the general formula: STR1 wherein R1 is amino or a protected amino R2 is lower alkyl which may have 1 to 3 halogens R3 is COO?, carboxy or a protected carboxy R4 is hydroxy(lower)alkyl or protected hydroxy(lower)alkyl R5 is amino or a protected amino R6 is hydrogen or lower alkyl X? is an anion, and n is 0 or 1 with proviso that (i) when R3 is COO?, then n is 0, and (ii) when R3 is carboxy or a protected carboxy, then n is 1, and pharmaceutically acceptable salt thereof.